Literature DB >> 34389857

Reperfusion therapies and in-hospital outcomes for ST-elevation myocardial infarction in Europe: the ACVC-EAPCI EORP STEMI Registry of the European Society of Cardiology.

Uwe Zeymer1, Peter Ludman2, Nicolas Danchin3, Petr Kala4, Cécile Laroche5, Masoumeh Sadeghi6, Roberto Caporale7, Sameh Mohamed Shaheen8, Jacek Legutko9, Zaza Iakobsishvili10, Khalid F Alhabib11, Zuzana Motovska12, Martin Studencan13, Jorge Mimoso14, David Becker15, Dimitrios Alexopoulos16, Zviad Kereseselidze17, Sinisa Stojkovic18, Parounak Zelveian19, Artan Goda20, Erkin Mirrakhimov21,22, Gani Bajraktari23, Hasan Al-Farhan24, Pranas Šerpytis25, Bent Raungaard26, Toomas Marandi27, Alice May Moore28, Martin Quinn29, Pasi Paavo Karjalainen30, Gabriel Tatu-Chitolu31, Chris P Gale32, Aldo P Maggioni5,33, Franz Weidinger34.   

Abstract

AIMS: The aim of this study was to determine the contemporary use of reperfusion therapy in the European Society of Cardiology (ESC) member and affiliated countries and adherence to ESC clinical practice guidelines in patients with ST-elevation myocardial infarction (STEMI). METHODS AND
RESULTS: Prospective cohort (EURObservational Research Programme STEMI Registry) of hospitalized STEMI patients with symptom onset <24 h in 196 centres across 29 countries. A total of 11 462 patients were enrolled, for whom primary percutaneous coronary intervention (PCI) (total cohort frequency: 72.2%, country frequency range 0-100%), fibrinolysis (18.8%; 0-100%), and no reperfusion therapy (9.0%; 0-75%) were performed. Corresponding in-hospital mortality rates from any cause were 3.1%, 4.4%, and 14.1% and overall mortality was 4.4% (country range 2.5-5.9%). Achievement of quality indicators for reperfusion was reported for 92.7% (region range 84.8-97.5%) for the performance of reperfusion therapy of all patients with STEMI <12 h and 54.4% (region range 37.1-70.1%) for timely reperfusion.
CONCLUSIONS: The use of reperfusion therapy for STEMI in the ESC member and affiliated countries was high. Primary PCI was the most frequently used treatment and associated total in-hospital mortality was below 5%. However, there was geographic variation in the use of primary PCI, which was associated with differences in in-hospital mortality. Published on behalf of the European Society of Cardiology. All rights reserved.
© The Author(s) 2021. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Observational studies; Primary percutaneous coronary intervention; Reperfusion therapy; ST-elevation myocardial infarction

Mesh:

Year:  2021        PMID: 34389857     DOI: 10.1093/eurheartj/ehab342

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  5 in total

1.  Plasma Exosome miRNAs Profile in Patients With ST-Segment Elevation Myocardial Infarction.

Authors:  Ruicong Guan; Kuan Zeng; Bin Zhang; Minnan Gao; Jianfen Li; Huiqi Jiang; Yuqiang Liu; Yongjia Qiang; Zhuxuan Liu; Jingwen Li; Yanqi Yang
Journal:  Front Cardiovasc Med       Date:  2022-06-15

2.  D-dimer to Creatinine Ratio: A Novel Biomarker Associated with Gensini Score in ST-Segment Elevation Myocardial Infarction Patients.

Authors:  Jiaojiao Yang; Yingjie Zhao; Yong Li; Jianmin Tang; Yipin Zhao
Journal:  Clin Appl Thromb Hemost       Date:  2022 Jan-Dec       Impact factor: 3.512

3.  Patient characteristics, treatment strategy, outcomes, and hospital costs of acute coronary syndrome: 3 years of data from a large high-volume centre in Central Europe.

Authors:  Petr Toušek; David Bauer; Marek Neuberg; Markéta Nováčková; Petr Mašek; Petr Tu Ma; Viktor Kočka; Zuzana Moťovská; Petr Widimský
Journal:  Eur Heart J Suppl       Date:  2022-03-30       Impact factor: 1.624

Review 4.  Cytokine storm: behind the scenes of the collateral circulation after acute myocardial infarction.

Authors:  Weixin He; Peixian Chen; Qingquan Chen; Zongtong Cai; Peidong Zhang
Journal:  Inflamm Res       Date:  2022-07-25       Impact factor: 6.986

5.  Late myocardial reperfusion in ST-elevation myocardial infarction: protocol for a systematic review and meta-analysis.

Authors:  Rodrigo Vargas-Fernández; Manuel Chacón-Diaz; Gianfranco W Basualdo-Meléndez; Francisco A Barón-Lozada; Fabriccio J Visconti-Lopez; Daniel Comandé; Akram Hernández-Vásquez
Journal:  BMJ Open       Date:  2022-09-14       Impact factor: 3.006

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.